Yuhan Corporation (KRX:000100)
South Korea · Delayed Price · Currency is KRW 83,700
-1,200 (-1.41%)
At close: Aug 31, 2026
Yuhan Revenue
Yuhan had revenue of 639.45B KRW in the quarter ending June 30, 2026, with 10.44% growth. This brings the company's revenue in the last twelve months to 2.28T, up 5.40% year-over-year. In the year 2025, Yuhan had annual revenue of 2.19T with 5.75% growth.
Revenue (ttm)
2.28T
Revenue Growth
+5.40%
P/S Ratio
2.74
Revenue / Employee
1.09B
Employees
2,087
Market Cap
6.24T
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.19T | 118.85B | 5.75% |
| Dec 31, 2024 | 2.07T | 208.81B | 11.23% |
| Dec 31, 2023 | 1.86T | 83.14B | 4.68% |
| Dec 31, 2022 | 1.78T | 88.04B | 5.22% |
| Dec 31, 2021 | 1.69T | 67.95B | 4.19% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Daewoong | 2.12T |
| GC Biopharma | 1.96T |
| Chong Kun Dang Pharmaceutical | 1.78T |
| Hanmi Pharm. | 1.66T |
| Daewoong Pharmaceutical | 1.64T |
| Dong-A Socio Holdings | 1.52T |
| Boryung | 1.06T |
| JW Pharmaceutical | 820.86B |